Sodium Phenylbutyrate and Ursodoxicoltaurine (Albrioza)

Abstract


 CADTH recommends that Albrioza be reimbursed by public drug plans for the treatment of patients with amyotrophic lateral sclerosis (ALS) if certain conditions are met.
 Albrioza should only be covered to treat those who have a diagnosis of definite ALS, have had symptoms for 18 months or less, have a forced vital capacity (FVC) of at least 60% of predicted, and do not require permanent noninvasive or invasive breathing support.
 Albrioza should only be reimbursed if prescribed by a specialist with experience diagnosing and managing ALS and if the cost is reduced.